Clinical trials
Completed Phase 2 Metabolic Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
76 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2003 | 3 |
| 2004 | 7 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 6 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 76 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Guadalajara | 5 |
| University of Pennsylvania | 3 |
| Emory University | 2 |
| Florida State University | 2 |
| Johns Hopkins University | 2 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| National Institute on Aging (NIA) | 2 |
| University of Alberta | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Metabolic Syndrome | 76 |
| Insulin Resistance | 29 |
| Obesity | 20 |
| Diabetes Mellitus | 12 |
| Diabetes Mellitus, Type 2 | 11 |
| Hypertension | 11 |
| Cardiovascular Diseases | 10 |
| Glucose Intolerance | 6 |
| Atherosclerosis | 5 |
| Dyslipidemias | 5 |
Trials
Showing 1 to 25 of 76. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.